Missoula speakers report illnesses, long-term risks from pesticide sprays

Speakers at a Missoula public meeting described acute illnesses and chronic health effects they attribute to pesticide sprays and urged stronger government oversight and public warnings. The presenters named specific chemicals — including malathion and Captan — and cited federal testing gaps and alleged industry data fraud.

The issue matters locally because speakers said sprays affected homes, schools and a university campus and raised broader questions about federal oversight of pesticide registration and residue testing. Presenters warned that children, pregnant women and farmworkers are especially vulnerable.

A presenter who identified herself as a public speaker opened with a warning about birth defects and pesticides: "The birth defects you are about to see have been linked to pesticide exposure." She said Captan is a suspected teratogen and compared chemical risks to historical thalidomide injuries. The presenter also described neurotoxic effects linked in scientific reports to low-level pesticide exposure, including "poor performance on tests, damage to academic skills, motor skills, memory disturbances, inability to focus attention, increased anxiety and emotional problems."

Several residents gave first-person accounts. Maureen, identified at the meeting as a resident who said she had prior pesticide exposure, said, "I had contact with a weed killer that caused me to lose control of my legs. I had to retrain myself to walk for about 4 or 5 months." Maureen told the meeting she spent thousands of dollars on medical care before an article about herbicide effects led clinicians to her exposure.

A family described a hospitalization after a nearby state spray event. According to the meeting record, a Missoula-area resident was reportedly taken by helicopter to Phoenix after a convulsion following an overnight spray; hospital staff initially gave atropine and later a cholinesterase test showed an RBC cholinesterase of 3.5, which family members said was "half of low normal." Meeting speakers said toxicology specialists later administered pralidoxime (an antidote) and that the patient responded to that treatment.

Presenters and commenters emphasized two regulatory concerns: gaps in reregistration and limited residue testing. The meeting record cited the 1972 amendment to the federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) requiring reregistration and said EPA reregistration has proceeded slowly, leaving many active ingredients with "data gaps." Speakers said the Food and Drug Administration inspects a small fraction of imported produce for residues and cited cases where pesticides banned in the U.S. were used on crops abroad and reimported.

Speakers also raised the issue of so-called "inert" ingredients in pesticide formulations. The presenter said many inert ingredients are not disclosed on labels and asserted that some inerts can be more toxic than the active ingredient. The transcript references Industrial BioTest Labs and an FBI/federal grand jury indictment history, noting alleged fraud in safety studies used to register some pesticides.

Several speakers described community-scale effects: absenteeism after school spraying, prolonged flu-like fatigue among nearby residents, new sensitivities to perfumes and other chemicals after an exposure, and concern about pesticide drift reaching yards and play areas. The presenter said a university was considering evening MCPA spraying on campus and voiced concern about students using lawns soon afterward because MCPA can be absorbed through the skin.

Speakers urged stronger public-warning requirements and criticized statements that various pesticides are "safe" when they said many chemicals lack chronic-toxicity testing. The meeting record quotes one speaker saying, "Say no to pesticides." Presenters asked Congress and federal agencies to act on reregistration, data gaps and disclosure of inert ingredients.

No formal motions or official actions were recorded in the transcript provided; the content consisted of public remarks, personal testimony and citations of federal regulatory history and scientific findings. Several speakers indicated the meeting recording would be shared on Missoula Community Access Television.

The transcript contains medical and technical claims raised by speakers and family members; those claims are presented here as reported at the meeting. Medical testing referenced (an RBC cholinesterase of 3.5) and historical dates cited by speakers (for example, an exposure described as July 7–9, 1989) are reported as discussed in the meeting.